Company intelligence / Profile preview

Reprogenix Bioscience

Hangzhou, Zhejiang, China

Ownership: Private
Development stage: Other

Overview

Reprogenix’s lead candidate, RGB5088, is a chemically-induced pluripotent stem cell-derived islet product that has demonstrated the first-ever achievement of insulin independence in type 1 diabetes patients following transplantation. In a published pilot clinical study, patients achieved insulin independence within 75 days post-transplantation with excellent glycemic control and no signs of malignancy. The product has received IND approval in China, Phase 1 trials are ongoing, and pivotal Phase 2/3 trials are planned to begin in 2026 with BLA filing targeted for late 2027

Therapeutic areas: Endocrinology
Modalities: Induced pluripotent stem cell derived therapyCell therapyGene editing
Industry: Biotech

Drug pipeline

1 asset

RGB5088

Partnerships

Academic collaborations with Peking University Stem Cell Research CenterZhejiang Province "Leading Goose" R&D Project Plan

Beyond the preview

Go deeper on Reprogenix Bioscience.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Reprogenix Bioscience.

Explore the full profile